Data-independent LC-MS/MS analysis of ME/CFS plasma reveals a dysregulated coagulation system, endothelial dysfunction, downregulation of complement machinery.
Nunes, Massimo, Vlok, Mare, Proal, Amy et al. · Cardiovascular diabetology · 2024 · DOI
Quick Summary
Researchers analyzed blood proteins in 15 ME/CFS patients and 10 healthy controls to look for differences that might explain ME/CFS symptoms. They found that ME/CFS patients had abnormal levels of proteins involved in blood clotting, blood vessel function, and immune system regulation. These findings suggest that problems with blood clotting and blood vessel health may play a role in ME/CFS.
Why It Matters
This study provides molecular evidence supporting the hypothesis that coagulation dysfunction and endothelial pathology contribute to ME/CFS pathophysiology, potentially explaining symptoms like orthostatic intolerance and post-exertion malaise. Identifying specific dysregulated proteins offers concrete targets for future biomarker development and therapeutic intervention in ME/CFS.
Observed Findings
24 proteins were significantly elevated and 21 were significantly reduced in ME/CFS plasma compared to controls
Coagulation-related proteins thrombospondin-1, platelet factor 4, and protein S showed abnormal expression patterns
Complement system proteins, particularly C9 (part of the membrane attack complex), were significantly downregulated
Immune markers including lactotransferrin and S100-A9 were elevated in ME/CFS samples
Protein expression patterns suggest concurrent dysregulation of blood clotting, endothelial function, and complement-mediated immunity
Inferred Conclusions
ME/CFS involves dysregulation of the coagulation system and abnormal endothelial function that may contribute to cardiovascular symptoms
Downregulation of complement machinery, particularly the terminal complement pathway, suggests impaired immune defense mechanisms
The constellation of findings implicates multiple interconnected biological systems (hemostasis, vasculature, immunity) in ME/CFS pathophysiology
ME/CFS patients may face elevated hematological and cardiovascular risk, especially in the context of comorbid metabolic conditions like diabetes
Remaining Questions
Do these protein abnormalities precede ME/CFS symptom onset or develop as a consequence of chronic illness?
What This Study Does Not Prove
This study identifies associations between protein levels and ME/CFS diagnosis but does not prove that these protein changes cause ME/CFS symptoms or drive disease progression. The small sample size limits generalizability, and the cross-sectional design cannot establish whether protein dysregulation precedes symptom onset or results from chronic illness. These findings require validation in larger, longitudinal studies and functional studies to establish causality.
How do these coagulation and endothelial abnormalities mechanistically produce specific ME/CFS symptoms like post-exertion malaise and orthostatic intolerance?
Are the identified proteins suitable as clinical biomarkers for ME/CFS diagnosis or severity stratification?
Do these dysregulated proteins differ between ME/CFS onset patterns (sudden vs gradual) or severity levels?